EUVIMEDEUVIMED entdecken
Crossref

Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM

Anna-Elisa Heipertz iD, Kristian W Pajtler iD, Elke Pfaff iD, Kathrin Schramm, Mirjam Blattner-Johnson, Till Milde iD, Barbara C Jones, Cecilia Zuliani iD, Caroline Hutter iD, Olli Lohi iD, Antonis Kattamis iD, Iwona Dachowska-Kalwak und 14 weitere

JCO Precision Oncology · 2023

DOI: 10.1200/po.23.00015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Anna-Elisa Heipertz und 25 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE INFORM is an international pediatric precision oncology registry, prospectively collecting molecular and clinical data of children with recurrent, progressive, or very high-risk malignancies. We have previously identified a subgroup of patients with improved outcomes on the basis of molecular profiling. The present analysis systematically investigates progression-free survival (PFS) and overall survival (OS) of patients receiving matching targeted treatment (MTT) with the most frequently applied drug classes and its correlation with underlying molecular alterations. METHODS A cohort of 519 patients with relapsed or refractory high-risk malignancies who had completed a follow-up of at least 2 years or shorter in the case of death or loss to follow-up was analyzed. Survival times were compared using the log-rank test. RESULTS MTT with anaplastic lymphoma kinase (ALK), neurotrophic tyrosine receptor kinase (NTRK), and B-RAF kinase (BRAF) inhibitors showed significantly improved PFS ( P = .012) and OS ( P = .036) in comparison with conventional treatment or no treatment. However, analysis of the four most commonly applied MTT groups, mitogen-activated protein kinase (MEK- n = 19), cyclin-dependent kinase (CDK- n = 23), other kinase (n = 62), and mammalian-target of rapamycin (mTOR- n = 20) inhibitors, did not reveal differences in PFS or OS compared with conventional treatment or no treatment in patients with similar molecular pathway alterations. We did not observe differences in the type of pathway alterations (eg, copy number alterations, single-nucleotide variants, InDels, gene fusions) addressed by MTT. CONCLUSION Patients with respective molecular alterations benefit from treatment with ALK, NTRK, and BRAF inhibitors as previously described. No survival benefit was observed with MTT for mutations in the MEK, CDK, other kinase, or mTOR signaling pathways. The noninterventional character of a registry has to be taken into account when interpreting these data and underlines the need for innovative interventional biomarker–driven clinical trials in pediatric oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinomaAnimalsHumansChildAdolescentProto-Oncogene Proteins B-rafPrecision MedicineNeoplasm Recurrence, LocalReceptor Protein-Tyrosine KinasesTOR Serine-Threonine KinasesMitogen-Activated Protein Kinase KinasesMammals

Substanzen

Antineoplastic AgentsProto-Oncogene Proteins B-rafReceptor Protein-Tyrosine KinasesTOR Serine-Threonine KinasesMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
  • German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Heidelberg Medical Faculty, University of Heidelberg, Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), Heidelberg, Germany.

ORCID-Profile: Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Till Milde, Cecilia Zuliani, Caroline Hutter, Olli Lohi, Antonis Kattamis, Anna Nilsson, Karin P S Langenberg, Bianca Goemans, C Michel Zwaan, Natalie Jäger, Uta Dirksen, David T W Jones, Annette Kopp-Schneider, Cornelis M van Tilburg

Zitieren

APA

Heipertz, A. E., Pajtler, K. W., Pfaff, E., Schramm, K., Blattner-Johnson, M., Milde, T., Jones, B. C., Zuliani, C., Hutter, C., Lohi, O., Kattamis, A., Dachowska-Kalwak, I., Nilsson, A., Gerber, N. U., Langenberg, K. P. S., Goemans, B., Zwaan, C. M., Molenaar, J. J., Jäger, N., …, & van Tilburg, C. M. (2023). Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO Precision Oncology. https://doi.org/10.1200/po.23.00015

Vancouver

Heipertz AE, Pajtler KW, Pfaff E, Schramm K, Blattner-Johnson M, Milde T, et al. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO Precision Oncology. 2023. doi:10.1200/po.23.00015

BibTeX
@article{Heipertz2023,
  author = {Heipertz, Anna-Elisa and Pajtler, Kristian W and Pfaff, Elke and Schramm, Kathrin and Blattner-Johnson, Mirjam and Milde, Till and Jones, Barbara C and Zuliani, Cecilia and Hutter, Caroline and Lohi, Olli and Kattamis, Antonis and Dachowska-Kalwak, Iwona and Nilsson, Anna and Gerber, Nicolas U and Langenberg, Karin P S and Goemans, Bianca and Zwaan, C Michel and Molenaar, Jan J and Jäger, Natalie and Dirksen, Uta and Witt, Ruth and Pfister, Stefan M and Jones, David T W and Kopp-Schneider, Annette and Witt, Olaf and van Tilburg, Cornelis M},
  title = {Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.23.00015}
}
Kostenlos starten →